Four Peptides, One Stack, and a Clear Framework
Peptide stacking is where the peptide world gets both exciting and confusing. The idea is straightforward: instead of using one peptide at a time, you combine multiple peptides that target complementary mechanisms to produce a synergistic healing effect. The execution, though, is where most people go wrong. They pick peptides based on what they read on a forum, dose them according to someone else's protocol, and hope for the best.
Dr. Ashley Froese breaks down her preferred healing stack in this video: BPC-157, TB-500, GHK-Cu, and KPV. Each addresses a different aspect of the healing and regeneration process, and the combination produces outcomes that she says consistently exceed what any single peptide achieves alone. With 93K views and a clinician who actually prescribes these compounds to real patients, this is one of the more practical stacking videos available.
BPC-157: The Tissue Repair Foundation
BPC-157 (Body Protection Compound-157) is the anchor of most healing-focused peptide stacks, and for good reason. It is the most studied healing peptide in the preclinical literature, with over 100 published animal studies demonstrating accelerated repair in tendons, ligaments, muscles, bones, gut tissue, skin, and even neurological tissue. The breadth of the healing response is what makes BPC-157 unusual. Most compounds that promote healing in one tissue type have no effect in others. BPC-157 works across the board.
The primary mechanism involves nitric oxide system modulation. BPC-157 upregulates nitric oxide synthesis through the eNOS pathway, which increases blood flow to damaged tissue. More blood flow means more delivery of oxygen, nutrients, and immune cells to the injury site, and faster removal of inflammatory debris and metabolic waste products. It also upregulates several growth factors including VEGF (vascular endothelial growth factor), which promotes the formation of new blood vessels in healing tissue, a process called angiogenesis that is often the rate-limiting step in recovery from deep tissue injuries.
For gut healing specifically, BPC-157 has a unique advantage: it is derived from a protein naturally present in human gastric juice. Animal studies show it protects against and reverses damage from NSAIDs, alcohol, and various chemical irritants in the GI tract. It also appears to promote gastric motility and normalize intestinal function in models of GI dysfunction. This makes it particularly relevant for people dealing with gut permeability (leaky gut), inflammatory bowel conditions, or chronic NSAID-induced GI damage, which is common in athletes and anyone managing chronic pain.
Dr. Froese typically doses BPC-157 at 250-500mcg per day via subcutaneous injection, either once daily or split into two doses morning and evening. For gut-specific applications, some practitioners use oral BPC-157, though the data supporting oral administration is more limited than for injection. The logic behind oral dosing is that the peptide can act locally on gut tissue as it passes through the digestive tract, but bioavailability studies have not been conducted in humans to confirm this.
TB-500: Systemic Repair and Inflammation Control
TB-500 is a synthetic version of Thymosin Beta-4, a 43-amino-acid peptide that your body produces naturally and in significant quantities. Thymosin Beta-4 is one of the first peptides upregulated after tissue injury, and it plays a role in cell migration, blood vessel formation, and inflammation regulation. It is found in high concentrations in wound fluid, platelets, and white blood cells, which tells you something about its biological importance in the healing response.
Where BPC-157 tends to work locally (greatest effect near the injection site or in the GI tract), TB-500 has more systemic effects. It distributes throughout the body regardless of injection location, which makes it useful for conditions involving widespread inflammation or multiple injury sites. Some practitioners describe TB-500 as the peptide that sets the stage for healing by reducing the inflammatory environment that prevents repair from progressing past the initial damage phase.
The mechanism is distinct from BPC-157 and operates through a different set of cellular pathways. TB-500 works primarily through actin regulation. Actin is a protein that forms the structural scaffolding of cells and is essential for cell movement, division, and wound closure. By modulating actin dynamics and promoting the formation of actin-based cell projections called lamellipodia, TB-500 helps cells migrate to injury sites more efficiently. Cell migration is one of the rate-limiting steps in tissue repair, particularly for deep injuries where repair cells need to travel significant distances from blood vessels to the center of the damaged zone.
TB-500 also has demonstrated cardioprotective effects in animal models. Studies in mice with induced cardiac injury showed that TB-500 promoted cardiac repair, reduced scar formation, and improved functional recovery of the heart muscle. While this has not been studied in human cardiac patients, it suggests the peptide has tissue-protective effects that extend beyond musculoskeletal healing into organ systems where repair capacity is normally very limited.
Typical dosing is 2-5mg per week, usually split into two or three subcutaneous injections. Some protocols use a loading phase of 5-10mg per week for the first 2-4 weeks to establish tissue saturation, then taper to a maintenance dose of 2-2.5mg per week.
GHK-Cu: Remodeling and Scar Prevention
GHK-Cu is the peptide in this stack that addresses what happens after the initial repair is complete. Healing is not just about closing the wound or reconnecting the torn fibers. It is about the quality of the repair. Poor-quality healing produces scar tissue, fibrosis, and adhesions that limit function and increase the risk of re-injury. This is why many chronic injuries never fully resolve: the body heals them, but it heals them badly, replacing functional tissue with non-functional scar tissue that cannot contract, stretch, or transmit force normally.
GHK-Cu modulates the expression of over 4,000 genes involved in tissue remodeling, collagen synthesis, and antioxidant defense. In the context of a healing stack, GHK-Cu serves as the remodeling agent. BPC-157 and TB-500 accelerate the initial repair. GHK-Cu ensures that the repaired tissue is structurally sound and organized rather than a disorganized mass of scar tissue. It promotes the synthesis of new, properly organized collagen fibers and helps break down and reorganize existing scar tissue through matrix metalloproteinase regulation.
The anti-fibrotic effect of GHK-Cu is particularly valuable for chronic injuries where fibrosis has already developed. Old scar tissue in muscles, tendons, and fascia can be gradually remodeled over time when GHK-Cu is administered as part of a healing protocol. This is one of the reasons some practitioners use this stack for injuries that are months or years old, not just acute injuries where the initial repair is still in progress.
Dosing for GHK-Cu in a systemic stack is typically 200-500mcg per day via subcutaneous injection. For skin-specific applications, topical GHK-Cu can be used in addition to or instead of injection, with concentrations ranging from 0.01% to 1% in clinical settings.
KPV: The Anti-Inflammatory Anchor
KPV is a tripeptide (lysine-proline-valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It has potent anti-inflammatory effects that work through a different pathway than NSAIDs, corticosteroids, or other conventional anti-inflammatory agents, which is why it can complement them rather than duplicating their effects.
KPV enters cells and directly inhibits NF-kB, the master regulator of inflammatory gene expression. When NF-kB is overactive, it drives the production of inflammatory cytokines like TNF-alpha, IL-6, and IL-1beta. These cytokines are necessary for the initial inflammatory phase of healing (you need some inflammation to trigger the repair cascade and recruit immune cells to the damage site), but when they persist beyond the acute phase, they prevent healing from progressing to the proliferative and remodeling stages. KPV helps shut down the sustained inflammation that keeps chronic injuries in a perpetual state of non-healing.
Dr. Froese describes KPV as especially useful for patients with gut inflammation (IBD, colitis, chronic enteritis) and for those with injuries that seem stuck in a cycle of recurring inflammation. When an injury has been inflamed for weeks or months without progressing toward resolution, the inflammatory environment itself becomes the problem. KPV breaks that cycle. In a stack context, KPV controls the inflammatory environment while BPC-157 and TB-500 drive the repair process and GHK-Cu manages the remodeling.
Dosing is typically 200-500mcg per day subcutaneously for systemic applications, or oral for gut-specific applications where the peptide can act locally on intestinal tissue.
How the Stack Works Together
The logic of combining these four peptides follows the natural phases of tissue repair. Phase one is inflammation: KPV modulates this phase, reducing excessive inflammation without eliminating the necessary inflammatory signals that initiate repair. Phase two is proliferation: BPC-157 and TB-500 accelerate this phase, promoting cell migration, blood vessel formation, and new tissue growth. Phase three is remodeling: GHK-Cu improves this phase, ensuring that newly formed tissue is properly organized with functional collagen architecture rather than disorganized scar tissue.
By targeting all three phases simultaneously, the stack compresses the healing timeline and improves the quality of the final result. Dr. Froese reports that patients using the full stack typically see meaningful improvement within 2-4 weeks for acute injuries and 6-12 weeks for chronic conditions, compared to 4-8 weeks and 3-6 months respectively for single-peptide protocols.
Practical Considerations for Running This Stack
Cost is the first concern. Running four peptides simultaneously from a compounding pharmacy can cost $300-$600 per month depending on doses and pharmacy pricing. This is a significant investment, and it makes sense to have a clear clinical goal and a defined treatment duration rather than running the stack indefinitely without evaluating results.
Injection volume is the second consideration. Four subcutaneous injections per day is a lot, both practically and in terms of patient compliance. Some practitioners combine compatible peptides in the same syringe to reduce injection burden. BPC-157 and TB-500 are commonly combined in a single injection. GHK-Cu and KPV can be combined separately. This brings the injection count down to two per day, which is more manageable for most people.
Monitoring should include inflammatory markers (CRP, ESR), imaging if appropriate (ultrasound or MRI for structural injuries), and functional assessments (range of motion, pain scales, grip strength, or other relevant performance tests). Do not rely solely on how you feel. Objective markers tell you whether the healing is actually progressing at the tissue level, which may lag behind or lead your subjective experience.
Duration depends on the condition. Acute injuries may need only 4-6 weeks of the full stack. Chronic conditions often require 8-16 weeks. After the primary healing phase, many practitioners taper to a single maintenance peptide (usually BPC-157 or GHK-Cu) rather than continuing the full stack. The stack is a tool for a specific purpose and timeframe, not a permanent lifestyle addition.